Get the Stockscreener App
0.9706
1.75%
-0.0204
Prokidney Corp stock is traded at $0.9706, with a volume of 20,467.
It is down -1.75% in the last 24 hours and down -35.94% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
See More
Previous Close:
$0.991
Open:
$0.991
24h Volume:
20,467
Relative Volume:
0.05
Market Cap:
$126.82M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-1.7028
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+2.20%
1M Performance:
-35.94%
6M Performance:
-60.42%
1Y Performance:
-33.31%
1-Day Range:
$0.9633
$1.03
1-Week Range:
$0.94
$1.07
52-Week Range:
$0.94
$4.44
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
0.9633 | 126.82M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.17 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
670.62 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
617.07 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.90 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.69 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney Corp reports results for the quarter ended December 31Earnings Summary - TradingView
ProKidney Hold Rating: Balancing Developmental Progress and Financial Stability Amid Uncertainty - TipRanks
ProKidney Corp (PROK) Reports $163.3 Million Net Loss for 2024, - GuruFocus.com
ProKidney reports larger loss in 2024 as production resumes - Winston-Salem Journal
PROKIDNEY CORP. SEC 10-K Report - TradingView
ProKidney CEO cites 'significant progress' after regenerative medicine company loses $163M in 2024 - The Business Journals
ProKidney reports FY24 EPS (62c), consensus (59c) - TipRanks
ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease - Nasdaq
ProKidney Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
FDA Fast-Tracks ProKidney's CKD Treatment: $358M War Chest Fuels Breakthrough Development - StockTitan
Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
ProKidney (PROK) Expected to Announce Quarterly Earnings on Thursday - Defense World
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Simply Wall St
ProKidney (NASDAQ:PROK) Stock Price Down 2.7%Here's What Happened - MarketBeat
ProKidney stock hits 52-week low at $1.34 amid market challenges - Investing.com Australia
ProKidney stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
Head to Head Review: ProKidney (NASDAQ:PROK) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK), - Yahoo Finance
ProKidney Corp (NASDAQ: PROK) Has Great Upside Potential - Stocks Register
ProKidney Corp [PROK] Chief Regulatory Officer makes an insider sale of 16,412 shares worth 41,030. - Knox Daily
JPMorgan Chase & Co. Purchases 18,472 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm - The Malaysian Reserve
2025 Will Be A Major Year For ProKidney’s Rilparencel In CKD Treatment (NASDAQ:PROK) - Seeking Alpha
US Penny Stocks: 3 Picks With Market Caps Under $300M - Simply Wall St
ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site - The Business Journals
ProKidney's high-profile Greensboro plant initiative ends with planned $20 million sale of property - Winston-Salem Journal
ProKidney (NASDAQ:PROK) Trading 8.7% HigherStill a Buy? - MarketBeat
Insiders In ProKidney Still Down 26% On US$54.7m Investment - Simply Wall St
Barclays PLC Has $281,000 Position in ProKidney Corp. (NASDAQ:PROK) - Defense World
568,647 Shares in ProKidney Corp. (NASDAQ:PROK) Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat
Jane Street Group LLC Has $78,000 Stock Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney Corp (PROK) Analyst Thoughts: How High Can It Go? - Stocks Register
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ProKidney to Present at J.P. Morgan Healthcare Conference, Spotlight on CKD Cell Therapy - StockTitan
Geode Capital Management LLC Grows Stock Position in ProKidney Corp. (NASDAQ:PROK) - Defense World
Geode Capital Management LLC Raises Stake in ProKidney Corp. (NASDAQ:PROK) - MarketBeat
Barclays PLC Purchases 124,667 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World
One ProKidney Insider Raised Their Stake In The Previous Year - Yahoo Finance
Stories to Watch in 2025: Will ProKidney change its Winston-Salem plans after abandoning $458M Greensboro facility? - The Business Journals
Cortexyme (NASDAQ:CRTX) vs. ProKidney (NASDAQ:PROK) Head to Head Comparison - Defense World
State Street Corp Has $2.74 Million Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Shares Gap UpStill a Buy? - MarketBeat
TBJ's Top 24 of '24: ProKidney backs out of Guilford deal, invests in W-S facilities (No. 4) - Triad Business Journal
ProKidney (NASDAQ:PROK) Stock Price Down 2.5%Here's What Happened - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 6.2%Should You Buy? - MarketBeat
ProKidney (NASDAQ:PROK) Shares Down 4.8%Here's What Happened - MarketBeat
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):